Suen Jacqueline K, Bressler Linda, Shord Stacy S, Warso Michael, Villano John Lee
Department of Medicine, Section of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA.
Anticancer Drugs. 2007 Aug;18(7):827-9. doi: 10.1097/CAD.0b013e32809ef9e0.
Cetuximab (Erbitux) is a recombinant, chimeric monoclonal antibody that binds with high affinity to the extracellular ligand-binding domain of human epidermal growth factor receptor. We report a case of repeated responses to cetuximab in a patient with nonresectable squamous cell skin cancer having strong human epidermal growth factor receptor expression. Nonmelanoma skin cancer is the most common cancer in the US, with more than 1 million new cases detected annually, of which 20-25% are squamous cell carcinomas. Although most primary cutaneous squamous cell carcinomas have a high clinical cure rate and are easily treated, the small subset of cancers that recur or metastasize has a poor prognosis, and accounts for approximately 2000 deaths per year. Treatment with cetuximab should be considered for human epidermal growth factor receptor expressing tumors in a palliative setting.
西妥昔单抗（爱必妥）是一种重组嵌合单克隆抗体，可与人表皮生长因子受体的细胞外配体结合域高亲和力结合。我们报告了1例人表皮生长因子受体表达强的不可切除性皮肤鳞状细胞癌患者对西妥昔单抗反复产生反应的病例。非黑色素瘤皮肤癌是美国最常见的癌症，每年新发病例超过100万，其中20%-25%为鳞状细胞癌。尽管大多数原发性皮肤鳞状细胞癌临床治愈率高且易于治疗，但复发或转移的一小部分癌症预后较差，每年约导致2000人死亡。对于在姑息治疗环境中表达人表皮生长因子受体的肿瘤，应考虑使用西妥昔单抗进行治疗。
